Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
NCT06550141Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Aug 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS). Started Sep 2024; status: recruiting.
02
Drugs
emapalumab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT06550141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550141.